Laboré
Poster preview: Evaluating the Efficacy of Glutamate Amino Acid Surfactants and Encapsulated Salicylic Acid in Acne Cleansers: A Clinical Study on Sensitive SkinPDF
17th ASCS Conference · 2025

Evaluating the Efficacy of Glutamate Amino Acid Surfactants and Encapsulated Salicylic Acid in Acne Cleansers: A Clinical Study on Sensitive Skin

Fatmawati M., Rezika V., Christianti M.A., Fajrin A.

Laboré Skin Research and Innovation Center

AcneSensitive Skin & Barrier

Abstract

A clinical study on sensitive skin evaluating an acne cleanser built on gentle glutamate amino-acid surfactants combined with encapsulated salicylic acid, balancing effective acne care through smart-delivery actives with the mildness required for a compromised skin barrier.

Key findings

  • Acne lesion size reduced 84.48% (p<0.05) after 14 days on dermatologist evaluation
  • TEWL reduced 25.33% (p<0.05), from 14.32 to 10.69 g/m²/h, indicating improved barrier function
  • Kill test on C. acnes achieved >99.998% at 30 seconds and >99.999% at 60 seconds contact time
  • Non-irritant with an irritation score of 0.00, hypoallergenic with 0 subjects showing sensitisation potential
  • Ophthalmologically tested with a maximum global ocular compatibility score of 4.0 ± 0.0
  • Microbiome NGS analysis showed no significant shift in skin bacterial composition between Day 0 and Day 14

Methods at a glance

Clinical arm
n = 35 female subjects
Protocol
7-day washout to Day 0, then 14 days of twice-daily use of the acne cleanser to Day 14
Microbiome sampling
Skin bacterial composition compared between Day 0 and Day 14
Safety
Hypoallergenic; no subject showed a reaction
Self-assessment
More than 80% of participants reported the cleanser did not leave their skin feeling stripped after 14 days, alongside overall improvement in skin tone and clarity

Background

Acne vulgaris differs from normal skin and becomes particularly complex in individuals with sensitive skin, where symptoms include an imbalanced skin microbiome, a tendency towards irritation and inflammation, higher transepidermal water loss and sensitivity to redness, burning and itching. Cleansing on acne skin should prepare the skin for topical treatments, support skin barrier function, remain non-comedogenic and non-acnegenic, maintain physiological pH and reduce C. acnes inflammation. Surfactants dissolve hydrophobic substances but are unable to differentiate between lipophilic intercellular lipids and lipophilic skin soils. Amino acid based surfactants are mild, with low toxicity, high biodegradability and sustainability, and glutamate amino acid surfactants can effectively remove dirt from the skin while preserving essential components of the skin barrier. Salicylic acid is a topical agent for acne treatment due to its keratolytic, comedolytic and anti-inflammatory properties, but conventional salicylic acid can cause prolonged erythema, dryness and excessive desquamation. Encapsulated salicylic acid reduces the potential for irritation, maintains stability and pH compatibility and preserves the chemical integrity of the active.

Objective

To evaluate the efficacy and tolerability of a mousse-type facial cleanser formulated with glutamate-based amino acid surfactants and encapsulated salicylic acid in the treatment of acne vulgaris in individuals with sensitive skin.

Materials and methods

The acne mousse cleanser was formulated with 10% active disodium cocoyl glutamate (DCG) and cocamidopropyl betaine (CAPB), 0.5% encapsulated salicylic acid (ENSA), bifida ferment lysate, humectants and allantoin. Formulation testing covered pH, foam size measured with a Keyence VHX-7000 microscope, and stability at room temperature, under display, in a freezer at -4°C, under sun exposure and in ovens at 45°C and 50°C. A kill test on C. acnes was performed at 30 and 60 second contact times using SNI EN 1276:2019. A microbiome friendly test on the acne regimen involved 35 females with acne sensitive skin, a 7-day washout to Day 0, then 14 days of product use, with DNA extraction and NGS-based microbiome analysis at Day 14. Safety testing comprised a single patch test in 24 subjects over 9 days, a 4-phase HRIPT in 40 subjects over 28 days and an ophthalmologist test in 22 subjects. The clinical study enrolled 63 females with acne sensitive skin using the product twice daily for 14 days, assessed by dermatologist evaluation, instrumental measurement with Tewameter, Courage Khazaka and VISIA, and a questionnaire.

Results and discussion

The product pH was 4.5 to 5.5 and remained stable in accelerated conditions over 3 months in the oven and in long-term conditions over 1 year at room temperature. Product pH affects the skin and prevents C. acnes from growing excessively within physiological skin pH of 4.0 to 6.5. CAPB and DCG form mixed surfactant films with enhanced intermolecular interactions, increasing foam film elasticity and producing creamier, longer-lasting foam. The mousse foam creates a cushioning effect that significantly reduces friction during application and minimises mechanical irritation and inflammation. Average foam diameter measured 0.18 μm at 0 minutes, 0.24 μm at 5 minutes and 0.29 μm at 10 minutes. In the kill test on C. acnes, a 30-second contact time reduced bacteria from 1.5 x 10⁷ CFU/ml to 2.3 x 10² CFU/ml, a 4.81 log reduction and greater than 99.998% kill, while a 60-second contact time achieved a log reduction above 5.03 and a kill above 99.999%, so a minimum contact time of 60 seconds during cleansing is recommended. Microbiome testing showed the acne regimen did not significantly alter the microbial balance of the skin between Day 0 and Day 14, suggesting the products are microbiome friendly. Safety evaluation found the formula hypoallergenic with no subject showing sensitisation potential, non-irritant with an irritation score of 0.00, dermatologically tested and ophthalmologically tested with a maximum global ocular compatibility score of 4.0 ± 0.0. On efficacy, dermatologist evaluation recorded an 84.48% reduction in acne lesion size after 14 days (p<0.05), VISIA skin analysis showed a reduction in skin porphyrins, and TEWL fell 25.33% (p<0.05) from 14.32 g/m²/h at Day 0 to 10.69 g/m²/h at Day 14. For reference, acne patients have a significantly higher mean TEWL of 13.16 g/m²/h compared with 10.63 g/m²/h in normal controls. Disodium cocoyl glutamate cleanses effectively without compromising the skin barrier and, unlike harsh surfactants such as sodium lauryl sulfate, does not strip essential lipids or disrupt the skin's acid mantle, which was reflected in the questionnaire where more than 80% of participants reported the cleanser did not leave their skin feeling stripped or tight. Bifida ferment lysate as a microbiome-active ingredient helps balance the skin microbiota, disrupt acne biofilm formation and soothe inflammation.

Conclusion

The mousse-type facial cleanser formulated with the mild amino acid surfactant disodium cocoyl glutamate, encapsulated salicylic acid and bifida ferment lysate demonstrated significant efficacy in improving acne-prone sensitive skin. The product is non-irritant, hypoallergenic and ophthalmologically tested. The mousse foam and DCG surfactant ensured effective cleansing with less friction and without compromising the skin barrier, while encapsulated salicylic acid provided targeted anti-acne activity with controlled release, minimising irritation while reducing acne lesion size, and bifida ferment lysate supported skin microbiome balance and barrier repair. This synergistic formulation led to a significant decrease in TEWL of 25.33%, indicating enhanced barrier function, and reduced acne lesion size by 84.48%. VISIA skin analysis further supported these findings, showing a visible reduction in porphyrin levels and skin redness after 14 days of use, along with overall improvement in skin tone and clarity.

References

Literature cited by the authors on the source poster.

  1. 1.Muizzuddin, N., Marenus, K.D. & Maes, D.H. (1998). Factors defining sensitive skin and its treatment. American Journal of Contact Dermatitis, 9(3), 170-175. https://doi.org/10.1097/01634989-199809000-00007
  2. 2.Levin, J. (2016). The relationship of proper skin cleansing to pathophysiology, clinical benefits, and the concomitant use of prescription topical therapies in patients with acne vulgaris. Dermatologic Clinics, 34(2), 133-145. https://doi.org/10.1016/j.det.2015.11.001
  3. 3.Mukhopadhyay, P. (2011). Cleansers and their role in various dermatological disorders. Indian Journal of Dermatology, 56(1), 2. https://doi.org/10.4103/0019-5154.77542
  4. 4.Draelos, Z.D. (2017). The science behind skin care: cleansers. Journal of Cosmetic Dermatology, 17(1), 8-14. https://doi.org/10.1111/jocd.12469
  5. 5.Walters, R.M., Mao, G., Gunn, E.T. & Hornby, S. (2012). Cleansing formulations that respect skin barrier integrity. Dermatology Research and Practice, 2012, 1-9. https://doi.org/10.1155/2012/495917
  6. 6.Arif, T. (2015). Salicylic acid as a peeling agent: a comprehensive review. Clinical, Cosmetic and Investigational Dermatology, 455. https://doi.org/10.2147/ccid.s84765
  7. 7.Roncoroni, M.A., Romero, P., Montes, J., Bascialla, G., Rodríguez, R., Pons-Esparver, R.R., Mazadiego, L.F. & García-Mayoral, M.F. (2021). Enhancement of a foaming formulation with a zwitterionic surfactant for gas mobility control in harsh reservoir conditions. Petroleum Science, 18(5), 1409-1426. https://doi.org/10.1016/j.petsci.2021.08.004
  8. 8.Sukanjanapong, S., Ploydaeng, M. & Wattanakrai, P. (2024). Skin barrier parameters in acne vulgaris versus normal controls: a cross-sectional analytic study. Clinical, Cosmetic and Investigational Dermatology, Volume 17, 2427-2436. https://doi.org/10.2147/ccid.s476004
  9. 9.Podwojniak, A., Tan, I.J., Sauer, J., Neubauer, Z., Rothenberg, H., Ghani, H., Parikh, A.K. & Cohen, B. (2024). Acne and the cutaneous microbiome: a systematic review of mechanisms and implications for treatments. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20332
Back to all studies